Sulopenem - Iterum Therapeutics

Drug Profile

Sulopenem - Iterum Therapeutics

Alternative Names: CP-70,429; PF-03709270; PF-3,709,270; Sulopenem etzadroxil

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Iterum Therapeutics; Pfizer
  • Class Antibacterials; Penems
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gram-negative infections; Gram-positive infections
  • Discontinued Bacterial infections

Most Recent Events

  • 11 Dec 2017 Iterum Therapeutics plans to initiate a phase III trial in Urinary tract infections (Combination therapy) (IV) (NCT03357614)
  • 11 Dec 2017 Iterum Therapeutics plans to initiate a phase III trial in Intra abdominal infections (Combination therapy) (IV) (NCT03358576)
  • 04 Oct 2017 Pharmacokinetics data from a phase I trial in Healthy volunteers were presented at the IDWeek 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top